Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity

NCT07304141 | Completed

• 1 other identifier: Dnr 2023-04013-01
• Study Type: observational
• Target: 128
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of the study is to examine the effects of pharmacological treatment for obesity on BMI trajectories and metabolic markers among patients in routine clinical care. A retrospective observational study. By collecting and analysing real-life data from the first children and adolescents in Sweden who have been offered pharmacological treatment for obesity, the results can contribute to a better understanding of how these treatments function in practice.

Conditions

Obesity (Disorder); Child Obesity

Keywords

liraglutide child obesity

Outcome Measures

Primary Outcomes (1)

• Change in Body Mass Index Standard Deviation Score (BMI SDS) over time

  The primary outcome, change in BMI SDS, will be evaluated at -12 months (pre-baseline), at baseline (0 months), and at +3-6, +12, and +18 months following treatment initiation.

Study Arms (1)

The study included adolescents aged 10-18 years with obesity who were offered liraglutide treatment

Other: Liraglutide 3 mg (Saxenda)

Interventions

Liraglutide 3 mg (Saxenda) OTHER

This is a retrospective observational study of adolescents aged 10-18 years with obesity who were offered liraglutide treatment at the Pediatric Clinic in Region Halland and at the Regional Childhood Obesity Center, Queen Silvia's Children's Hospital, Sahlgrenska University Hospital.

The study included adolescents aged 10-18 years with obesity who were offered liraglutide treatment

Eligibility Criteria

• Age: 10 Years - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Children at the Pediatric Clinic, Region Halland, and at the Regional Childhood Obesity Center, Queen Silvia's Children's Hospital.

You may qualify if:

• Adolescents aged 10-18 years with obesity who were offered pharmacological treatment
• Provided consent to participate
• Participants with short treatment duration, early adverse effects, or who proceeded to surgery are also included in baseline data

You may not qualify if:

• Hypothalamic obesity
• Craniopharyngioma
• Syndromic obesity / monogenic obesity

Sponsors & Collaborators

• Göteborg University: lead

Study Sites (1)

the Regional Childhood Obesity Center, Queen Silvia's Children's Hospital.

Gothenburg, 416 50, Sweden

Location

MeSH Terms

Conditions

Obesity; Pediatric Obesity

Interventions

Liraglutide

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Glucagon-Like Peptide 1; Glucagon-Like Peptides; Proglucagon; Gastrointestinal Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD PhD

Study Record Dates

• First Submitted: December 12, 2025
• First Posted: December 26, 2025
• Study Start: December 20, 2023
• Primary Completion: December 12, 2025
• Study Completion: December 12, 2025
• Last Updated: February 27, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

SE (1)